NEW ORLEANS -- Patients experiencing major heart attacks had a lower risk of serious complications if they received a single ...

A New York Times health reporter explains what clinical trials are, why they are important and how they can help inform us.

Adding the PCSK9 inhibitor evolocumab to standard lipid-lowering therapy significantly reduced first major cardiovascular ...

Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy ...

CARDIAMP CMI Cohort Results -- In the open-label rolling cohort (n=5), patients saw an average 80-second increase in exercise ...

Alixorexton, an investigational, oral, selective orexin 2 receptor agonist, demonstrated meaningful improvements across the trial’s dual primary endpoints of change from baseline in Maintenance of ...

Popular gut microbiome treatments for autism lack scientific support. Studies show probiotics likely aren't an effective ...

Amylin receptor agonists are gaining attention as a new class of anti-obesity drugs. Eloralintide, a novel and selective long ...

A new opinion paper shows no convincing evidence that there is a causal link between gut bacteria and autism, citing weak ...

Use of rifaximin soluble solid dispersion tablets for up to 24 weeks did not increase infection-related adverse events among patients with cirrhosis, according to data presented at ACG Annual ...

Merck & Co., Inc. acquires Cidara Therapeutics, Inc. for $9.2bn, boosting its pipeline with CD388's strong flu data. Click ...

Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 - - Reported highly positive 12-week primary endpoint results from Phase ...